Abbott Laboratories (ABT) Cash & Current Investments (2009 - 2026)

Abbott Laboratories has disclosed Cash & Current Investments across 18 years of filings, most recently posting $7.3 billion for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $7.3 billion, up 6.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 billion (up 6.59% YoY), and the FY2025 annual result was $8.9 billion, up 12.2% from the prior year.
• Cash & Current Investments came in at $7.3 billion for Q1 2026 at Abbott Laboratories, down from $8.9 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $10.2 billion in Q4 2022 to a low of $6.7 billion in Q1 2024.
• The 5-year median for Cash & Current Investments is $7.8 billion (2024), against an average of $8.1 billion.
• Across the five-year window, Cash & Current Investments gained 16.84% in 2023 and slumped 30.22% in 2024, its largest moves.
• Abbott Laboratories' Cash & Current Investments stood at $10.2 billion in 2022, then declined by 28.43% to $7.3 billion in 2023, then gained by 9.45% to $8.0 billion in 2024, then increased by 12.2% to $8.9 billion in 2025, then declined by 18.39% to $7.3 billion in 2026.
• The last three Cash & Current Investments figures came in at $7.3 billion (Q1 2026), $8.9 billion (Q4 2025), and $7.7 billion (Q3 2025), per Business Quant data.